STERIS (STE) Competitors $212.25 +0.25 (+0.12%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends STE vs. BDX, EW, RMD, IDXX, DXCM, PODD, HOLX, BAX, GMED, and TFXShould you be buying STERIS stock or one of its competitors? The main competitors of STERIS include Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), Insulet (PODD), Hologic (HOLX), Baxter International (BAX), Globus Medical (GMED), and Teleflex (TFX). These companies are all part of the "health care equipment" industry. STERIS vs. Becton, Dickinson and Company Edwards Lifesciences ResMed IDEXX Laboratories DexCom Insulet Hologic Baxter International Globus Medical Teleflex STERIS (NYSE:STE) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation, community ranking and profitability. Do insiders and institutionals believe in STE or BDX? 94.7% of STERIS shares are owned by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 1.1% of STERIS shares are owned by company insiders. Comparatively, 0.3% of Becton, Dickinson and Company shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate STE or BDX? STERIS presently has a consensus target price of $253.00, indicating a potential upside of 19.20%. Becton, Dickinson and Company has a consensus target price of $283.00, indicating a potential upside of 27.25%. Given Becton, Dickinson and Company's stronger consensus rating and higher probable upside, analysts clearly believe Becton, Dickinson and Company is more favorable than STERIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score STERIS 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Becton, Dickinson and Company 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer STE or BDX? Becton, Dickinson and Company received 262 more outperform votes than STERIS when rated by MarketBeat users. Likewise, 62.38% of users gave Becton, Dickinson and Company an outperform vote while only 58.98% of users gave STERIS an outperform vote. CompanyUnderperformOutperformSTERISOutperform Votes33558.98% Underperform Votes23341.02% Becton, Dickinson and CompanyOutperform Votes59762.38% Underperform Votes36037.62% Which has more risk and volatility, STE or BDX? STERIS has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Is STE or BDX a better dividend stock? STERIS pays an annual dividend of $2.28 per share and has a dividend yield of 1.1%. Becton, Dickinson and Company pays an annual dividend of $3.80 per share and has a dividend yield of 1.7%. STERIS pays out 52.1% of its earnings in the form of a dividend. Becton, Dickinson and Company pays out 64.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. STERIS has increased its dividend for 20 consecutive years and Becton, Dickinson and Company has increased its dividend for 53 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Which has preferable earnings and valuation, STE or BDX? Becton, Dickinson and Company has higher revenue and earnings than STERIS. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSTERIS$5.33B3.93$378.24M$4.3848.46Becton, Dickinson and Company$20.18B3.19$1.73B$5.9437.44 Does the media prefer STE or BDX? In the previous week, Becton, Dickinson and Company had 10 more articles in the media than STERIS. MarketBeat recorded 28 mentions for Becton, Dickinson and Company and 18 mentions for STERIS. STERIS's average media sentiment score of 1.50 beat Becton, Dickinson and Company's score of 1.41 indicating that STERIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 15 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Becton, Dickinson and Company 23 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is STE or BDX more profitable? Becton, Dickinson and Company has a net margin of 8.55% compared to STERIS's net margin of 8.02%. Becton, Dickinson and Company's return on equity of 14.89% beat STERIS's return on equity.Company Net Margins Return on Equity Return on Assets STERIS8.02% 13.78% 8.28% Becton, Dickinson and Company 8.55%14.89%6.98% SummaryBecton, Dickinson and Company beats STERIS on 13 of the 21 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get STERIS News Delivered to You Automatically Sign up to receive the latest news and ratings for STE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STE vs. The Competition Export to ExcelMetricSTERISSurgical appliances & supplies IndustryMedical SectorNYSE ExchangeMarket Cap$20.95B$9.70B$5.04B$19.90BDividend Yield1.04%1.10%5.17%3.54%P/E Ratio48.4622.00122.4242.67Price / Sales3.9330.911,179.2918.14Price / Cash15.6923.3733.5617.85Price / Book3.325.614.695.60Net Income$378.24M$182.72M$118.98M$985.93M7 Day Performance-4.49%44.47%-2.45%-0.19%1 Month Performance-5.94%-7.33%-4.03%0.15%1 Year Performance6.23%0.56%29.80%23.70% STERIS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STESTERIS4.9928 of 5 stars$212.25+0.1%$253.00+19.2%+6.2%$20.93B$5.14B48.4618,179Analyst ForecastPositive NewsBDXBecton, Dickinson and Company4.9899 of 5 stars$222.41-0.1%$283.00+27.2%-4.8%$64.35B$20.18B37.4473,000Positive NewsEWEdwards Lifesciences4.1259 of 5 stars$69.54-0.9%$75.67+8.8%+3.5%$41.01B$6.00B10.0319,800Short Interest ↓Analyst RevisionRMDResMed4.797 of 5 stars$241.55+1.4%$225.70-6.6%+59.7%$34.96B$4.69B31.999,980Positive NewsIDXXIDEXX Laboratories4.8654 of 5 stars$418.61+0.5%$552.38+32.0%-11.5%$34.09B$3.84B40.3711,000Positive NewsDXCMDexCom4.9834 of 5 stars$75.24+0.5%$104.59+39.0%-30.9%$29.25B$3.95B45.059,600PODDInsulet4.3867 of 5 stars$266.58+1.8%$253.27-5.0%+47.1%$18.38B$1.70B45.653,000HOLXHologic4.8572 of 5 stars$78.04-0.7%$89.91+15.2%+8.5%$18.13B$4.03B23.446,990BAXBaxter International4.8157 of 5 stars$32.63+0.3%$40.91+25.4%-8.4%$16.60B$15.06B163.1560,000GMEDGlobus Medical4.7045 of 5 stars$83.58+0.3%$88.18+5.5%+84.2%$11.38B$1.57B124.755,000Analyst DowngradePositive NewsTFXTeleflex4.8735 of 5 stars$187.47-2.9%$259.25+38.3%-12.7%$8.97B$2.97B37.2714,500Analyst Downgrade Related Companies and Tools Related Companies Becton, Dickinson and Company Alternatives Edwards Lifesciences Alternatives ResMed Alternatives IDEXX Laboratories Alternatives DexCom Alternatives Insulet Alternatives Hologic Alternatives Baxter International Alternatives Globus Medical Alternatives Teleflex Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:STE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding STERIS plc Please log in to your account or sign up in order to add this asset to your watchlist. Share STERIS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.